PPIDT00468
Drug Information
| Name | Sotrovimab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB16355 |
| Type | biotech |
| Indication | In Europe, sotrovimab is indicated for the treatment of COVID-19 in patients ≥12 years old and weighing ≥40kg who do not require supplemental oxygen and are at high risk of progressing to severe disease.[L39620] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution, concentrate | Intravenous |
62.5 mg/1mL
|
| Solution | Intravenous |
500 mg / 8 mL
|
| Injection, solution, concentrate | Intravenous |
500 mg/8ml
|